Univariable model, OR (95% CI) (n = 757–776) | Baseline model*OR (95% CI) (n = 767) | Longitudinal model⁋OR (95% CI) (n = 767) | |
---|---|---|---|
Baseline variable | |||
Age, 10 years | 0.87 (0.79–0.97) | 0.91 (0.82–1.01) | 0.92 (0.83–1.02) |
Female sex | 0.98 (0.73–1.30) | ‡ | ‡ |
Disease duration, 10 years | 0.81 (0.66–1.002) | 0.81 (0.65–1.02) | 0.78 (0.61–0.98) |
Obesity (BMI ≥ 25) | 0.71 (0.54–0.93) | 0.78 (0.59–1.04) | 0.77 (0.58–1.01) |
Ever-smokers | 0.73 (0.57–0.93) | 0.81 (0.63–1.04) | 0.83 (0.64–1.08) |
Positive HLA-B27 (vs. negative) | 1.63 (1.03–2.56) | 1.72 (1.09–2.71) | 1.71 (1.08–2.73) |
AS (vs. nr-axSpA) | 0.66 (0.45–0.96) | 0.71 (0.48–1.01) | 0.72 (0.49–1.06) |
TNFi naïve | 0.98 (0.73–1.31) | ‡ | ‡ |
Baseline ASDAS-CRP, unit | 0.77 (0.69–0.87) | 0.76 (0.68–0.86) | 0.78 (0.69–0.89) |
Longitudinal variable | |||
Follow-up time (vs. interval in the 1-year follow-up) | Reference | † | ‡ |
Interval in the 2-year follow-up | 0.98 (0.82–1.17) | † | ‡ |
Interval in the 3-year follow-up | 1.06 (0.83–1.36) | † | ‡ |
ASDAS-CRPt − 1, unit | 0.92 (0.86–0.98) | † | 0.95 (0.86–1.05) |
Concomitant NSAID use during the interval | 0.44 (0.35–0.56) | † | 0.45 (0.35–0.58) |
Concomitant sulfasalazine use during the interval | 0.31 (0.11–0.94) | † | 0.29 (0.09–0.90) |
Concomitant MTX use during the interval | 1.37 (0.76–2.44) | † | ‡ |
Group according to the interval DQ | |||
Control group (DQ = 100) | Reference | Reference | Reference |
Mild-tapering group (50 ≤ DQ < 100) | 1.21 (0.98–1.48) | 1.19 (0.96–1.48) | 0.89 (0.56–1.41) |
Heavy-tapering group (DQ < 50) | 0.44 (0.22–0.88) | 0.43 (0.22–0.85) | 0.27 (0.08–0.91) |
QIC of the model | 2059.054 | 2002.264 |